Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics has launched a Phase 1/2 clinical trial for its innovative CHM CDH17 CAR T cell therapy, targeting advanced gastrointestinal cancers at SCRI Oncology Partners in Nashville. The trial aims to establish a recommended dosage and assess the treatment’s safety and efficacy in patients with colorectal, gastric, and neuroendocrine tumors. This marks a significant advancement for Chimeric as it transitions this promising therapy from preclinical to clinical stage, highlighting an important step towards addressing a critical unmet medical need in cancer treatment.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
